Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has issued an update.
Jiangsu Hengrui Pharmaceuticals has scheduled a board meeting for March 25, 2026 to review and approve the annual results for the year ended December 31, 2025, and to decide on the publication of these results. The board will also consider the payment of a final dividend, a move that could influence shareholder returns and signal management’s view of the company’s recent financial performance.
The announcement, signed by chairman Sun Piaoyang, also reiterates the current composition of the board, highlighting a mix of executive, non-executive and independent non-executive directors. This governance structure underscores the company’s adherence to Hong Kong listing requirements and offers investors visibility into the leadership overseeing its strategic and financial decisions.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$96.90 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company listed in Hong Kong, operating through a board comprising executive, non-executive and independent non-executive directors. The company focuses on developing, manufacturing and selling pharmaceutical products, serving both domestic and international healthcare markets.
Average Trading Volume: 2,811,871
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$425.3B
Find detailed analytics on 1276 stock on TipRanks’ Stock Analysis page.